MiNK Therapeutics, Inc. (INKT)

Market Cap	30.85M
Revenue (ttm)	n/a
Net Income (ttm)	-22.46M
Shares Out	34.70M
EPS (ttm)	-0.65
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	37,583
Open	0.860
Previous Close	0.871
Day's Range	0.860 - 0.930
52-Week Range	0.750 - 3.340
Beta	0.12
Analysts	Strong Buy
Price Target	9.00 (+912.37%)
Earnings Date	May 9, 2024

About INKT

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It's product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and i...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 15, 2021
• Employees: 31
• Stock Exchange: NASDAQ
• Ticker Symbol: INKT

Analyst Forecast

According to one analyst, the rating for INKT stock is "Strong Buy" and the 12-month stock price forecast is $9.0.

Price Target

$9.0

(912.37% upside)

Analyst Consensus: Strong Buy